Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD of GeneDx Holdings Corp. from Q4 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
GeneDx Holdings Corp. quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents history and change rate from Q4 2018 to Q3 2025.
  • GeneDx Holdings Corp. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending September 30, 2025 was $97M, a 64.7% increase year-over-year.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

GeneDx Holdings Corp. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $97M +$38.1M +64.7% Sep 30, 2025 10-Q 2025-10-28
Q2 2025 $75.1M +$18M +31.6% Jun 30, 2025 10-Q 2025-07-29
Q1 2025 $101M +$16M +18.9% Mar 31, 2025 10-Q 2025-04-30
Q4 2024 $86.2M -$14.5M -14.4% Dec 31, 2024 10-Q 2025-10-28
Q3 2024 $58.9M -$29.4M -33.3% Sep 30, 2024 10-Q 2025-10-28
Q2 2024 $57.1M -$100M -63.8% Jun 30, 2024 10-Q 2025-07-29
Q1 2024 $84.7M -$130M -60.6% Mar 31, 2024 10-Q 2025-04-30
Q4 2023 $101M -$37.6M -27.2% Dec 31, 2023 10-Q 2025-10-28
Q3 2023 $88.3M -$117M -57.1% Sep 30, 2023 10-Q 2024-10-29
Q2 2023 $158M -$141M -47.3% Jun 30, 2023 10-Q 2024-07-30
Q1 2023 $215M -$101M -32% Mar 31, 2023 10-Q 2024-04-29
Q4 2022 $138M -$263M -65.6% Dec 31, 2022 10-K 2025-02-20
Q3 2022 $206M -$256M -55.5% Sep 30, 2022 10-Q 2023-11-03
Q2 2022 $299M +$262M +701% Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $316M +$246M +355% Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $401M +$283M +237% Dec 31, 2021 10-K 2024-02-23
Q3 2021 $462M +$322M +231% Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $37.3M Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $69.5M Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $119M +$3.95M +3.44% Dec 31, 2020 10-K 2023-03-16
Q3 2020 $140M Sep 30, 2020 10-Q 2021-11-15
Q4 2019 $115M +$114M +9663% Dec 31, 2019 10-K 2023-03-16
Q4 2018 $1.18M Dec 31, 2018 10-K 2022-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.